JP2018521651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521651A5 JP2018521651A5 JP2018500943A JP2018500943A JP2018521651A5 JP 2018521651 A5 JP2018521651 A5 JP 2018521651A5 JP 2018500943 A JP2018500943 A JP 2018500943A JP 2018500943 A JP2018500943 A JP 2018500943A JP 2018521651 A5 JP2018521651 A5 JP 2018521651A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- nucleic acid
- expression cassette
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108091026890 Coding region Proteins 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 241000700663 Avipoxvirus Species 0.000 claims description 4
- 241000700629 Orthopoxvirus Species 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 101100262328 Mus musculus Dct gene Proteins 0.000 claims description 2
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 claims description 2
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102000000763 Survivin Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 3
- 102100033130 T-box transcription factor T Human genes 0.000 claims 3
- 101710086566 T-box transcription factor T Proteins 0.000 claims 3
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 claims 1
- 241000700662 Fowlpox virus Species 0.000 claims 1
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- -1 antigenic epitope Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199681P | 2015-07-31 | 2015-07-31 | |
| US62/199,681 | 2015-07-31 | ||
| PCT/IB2016/001183 WO2017021776A1 (en) | 2015-07-31 | 2016-07-28 | Promoters for enhancing expression in poxviruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521651A JP2018521651A (ja) | 2018-08-09 |
| JP2018521651A5 true JP2018521651A5 (https=) | 2019-07-11 |
| JP6851364B2 JP6851364B2 (ja) | 2021-03-31 |
Family
ID=57068152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500943A Active JP6851364B2 (ja) | 2015-07-31 | 2016-07-28 | ポックスウイルスにおける発現を増強するためのプロモーター |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11753652B2 (https=) |
| EP (1) | EP3329016B1 (https=) |
| JP (1) | JP6851364B2 (https=) |
| KR (1) | KR102565284B1 (https=) |
| CN (1) | CN107922981B (https=) |
| AU (1) | AU2016303378B2 (https=) |
| CA (1) | CA2990549A1 (https=) |
| DK (1) | DK3329016T3 (https=) |
| ES (1) | ES2901468T3 (https=) |
| IL (1) | IL256869B (https=) |
| MX (1) | MX389312B (https=) |
| RU (1) | RU2753884C2 (https=) |
| SG (1) | SG10202000447YA (https=) |
| WO (1) | WO2017021776A1 (https=) |
| ZA (1) | ZA201800104B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050790B (zh) | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| KR20200100745A (ko) | 2017-12-19 | 2020-08-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| CA3119503A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| US20230190922A1 (en) | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| EP4452306A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| EP4648781A1 (en) | 2023-01-12 | 2025-11-19 | Bavarian Nordic A/S | Recombinant modified sarna (vrp) for cancer vaccine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| DK0538496T3 (da) * | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Rekombinant fjerkrækoppevirus med intakt FPV tk-gen |
| AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
| RU2180352C2 (ru) * | 1999-11-24 | 2002-03-10 | Государственный научный центр вирусологии и биотехнологии "Вектор" | ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР |
| EP2363493B1 (en) | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| NZ546443A (en) * | 2003-10-15 | 2009-11-27 | Virax Dev Pty Ltd | Poxvirus vector encoding retrovirus (eg HIV) and cytokine |
| WO2008106551A2 (en) * | 2007-02-28 | 2008-09-04 | The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. | Brachyury polypeptides and methods for use |
| CN101775410B (zh) * | 2009-01-09 | 2011-11-16 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种鸡痘病毒载体穿梭质粒及其应用 |
| MX2011010977A (es) * | 2009-04-17 | 2012-02-29 | Us Health | Composiciones inmunoterapeuticas combinadas contra cancer y metodos. |
| CN102321637A (zh) * | 2011-09-09 | 2012-01-18 | 中国人民解放军军事医学科学院军事兽医研究所 | 中国鸡痘病毒282e4弱毒株全基因组序列及其应用 |
| WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
-
2016
- 2016-07-28 ES ES16775852T patent/ES2901468T3/es active Active
- 2016-07-28 MX MX2018001055A patent/MX389312B/es unknown
- 2016-07-28 RU RU2018106643A patent/RU2753884C2/ru active
- 2016-07-28 WO PCT/IB2016/001183 patent/WO2017021776A1/en not_active Ceased
- 2016-07-28 KR KR1020187000086A patent/KR102565284B1/ko active Active
- 2016-07-28 SG SG10202000447YA patent/SG10202000447YA/en unknown
- 2016-07-28 CN CN201680042251.3A patent/CN107922981B/zh active Active
- 2016-07-28 DK DK16775852.3T patent/DK3329016T3/da active
- 2016-07-28 CA CA2990549A patent/CA2990549A1/en active Pending
- 2016-07-28 AU AU2016303378A patent/AU2016303378B2/en active Active
- 2016-07-28 JP JP2018500943A patent/JP6851364B2/ja active Active
- 2016-07-28 IL IL256869A patent/IL256869B/en unknown
- 2016-07-28 US US15/747,844 patent/US11753652B2/en active Active
- 2016-07-28 EP EP16775852.3A patent/EP3329016B1/en active Active
-
2018
- 2018-01-05 ZA ZA2018/00104A patent/ZA201800104B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521651A5 (https=) | ||
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| CA2741724C (en) | Promoters for recombinant viral expression | |
| JP6851364B2 (ja) | ポックスウイルスにおける発現を増強するためのプロモーター | |
| Baur et al. | Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses | |
| WO2012172277A4 (en) | Simian adenovirus and hybrid adenoviral vectors | |
| JP2016510989A5 (https=) | ||
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| JP2013507935A5 (https=) | ||
| CN1154069A (zh) | 多表位疫苗 | |
| JP2011234731A (ja) | ポックスウイルスゲノムへの異種遺伝子の組込みのためのベクター | |
| RU2019112725A (ru) | Композиции и способы для повышения стабильности трансгенов в поксвирусах | |
| JP2019528755A5 (https=) | ||
| JP2019500907A5 (https=) | ||
| Staib et al. | Improved host range selection for recombinant modified vaccinia virus Ankara | |
| JP2024535145A5 (https=) | ||
| JP2012513208A (ja) | 単一組換え系及びその使用方法 | |
| US20050287162A1 (en) | Recombinant fowlpox virus | |
| JP2004529646A (ja) | 病原性を低下させたウイルスベクター | |
| CN102732543B (zh) | 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗 | |
| Spencer | Matthew G. Cottingham, Rikke F. Andersen, Alexandra J. Spencer, Saroj Saurya, Julie Furze, Adrian VS Hill and Sarah C. Gilbert | |
| BRPI0705874B1 (pt) | seqüência geneticamente modificada do antígeno cs de plasmodium vivax, proteína recombinante cs e vírus geneticamente modificados que expressam o antígeno cs recombinante | |
| JP2019187249A (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| JPH02303482A (ja) | 日本悩炎ウイルスｎｓ１遺伝子組み換えワクチニアウイルス | |
| WO2004108940A2 (en) | Viral genome vectors |